Skip to main content
Premium Trial:

Request an Annual Quote

Tranzyme, Quark Biotech Pen Licensing, R&D Collaboration

NEW YORK, May 15 - Tranzyme and Quark Biotech have inked a multi-year research and licensing collaboration, Tranzyme said today.

 

Privately held Tranzyme will give Quark non-exclusive worldwide rights to its gene-expression and drug-discovery technologies TranzVector and TranzAssay in exchange for undisclosed annual research funding and milestone payments, the firms said.

 

In addition, Tranzyme, whose technology focuses on neurosensory diseases, will receive an equity investment from Quark and pocket undisclosed royalties from any products that happen to be developed.

 

Click here for more information.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.